A review of peritoneal mesothelioma at the Washington Cancer Institute

Surg Oncol Clin N Am. 2003 Jul;12(3):605-21, xi. doi: 10.1016/s1055-3207(03)00045-0.

Abstract

This article reviews a single institution's experience with 68 patients (21 females, 47 males) prospectively treated over the last 2 decades with an aggressive local-regional approach, combining maximal cytoreductive surgery with heated intraoperative intraperitoneal chemotherapy and early postoperative intraperitoneal chemotherapy. This multimodality treatment has resulted in a median survival of 67 months. Female patients had a significantly better prognosis than males. The other significant predictive factors of survival were: age, diagnosis by incidental findings, tumor extent, pathology, and completeness of cytoreduction.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
  • Biopsy, Needle
  • Chemotherapy, Adjuvant
  • Combined Modality Therapy / methods
  • District of Columbia
  • Female
  • Humans
  • Male
  • Mesothelioma / mortality
  • Mesothelioma / pathology*
  • Mesothelioma / therapy*
  • Middle Aged
  • National Institutes of Health (U.S.)
  • Neoplasm Staging
  • Peritoneal Neoplasms / mortality
  • Peritoneal Neoplasms / pathology*
  • Peritoneal Neoplasms / therapy*
  • Peritoneum / pathology
  • Peritoneum / surgery*
  • Prognosis
  • Prospective Studies
  • Randomized Controlled Trials as Topic
  • Risk Assessment
  • Survival Analysis
  • Treatment Outcome
  • United States